Status: Recruiting
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
Participants needed: 360
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Seaport TherapeuticsUpdated: Jul 13, 2026Locations: 61
Eligibility criteria
Participant is a male or female between 18 and 65 years of age, inclusive willin... [+5]
any depressive episode with psychotic or catatonic features. [+12]